Clinical Trial

The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

Name: The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease — clinical trial record (NCT06819514)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease

Trial Details

NCT Number	NCT06819514
Lead Sponsor	Guangzhou Jiayin Biotech Ltd
Conditions	Fabry Disease
Enrollment	16 participants
Start Date	2025-03-01
Primary Completion	2028-03-15 (estimated)
Study Completion	2028-03-15 (estimated)
Updated on ClinicalTrials.gov	2025-02-11